Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

Compared with standard-resolution OCT, HR-OCT does a better job of classifying and quantifying atrophic lesions associated with AMD. The current study attached special meaning to the quantitative ...

It launched in October 2019 in the US with sales predictions of $2.5 billion or more at peak, but sales slumped 43% in the first quarter of 2021 to $39 million. Wet AMD is a leading cause of ...

Wet AMD is caused by an overgrowth of blood vessels in the retina, the light-sensing tissue at the back of the eye. The vessels leak fluid or bleed, damaging the retina and causing vision loss.

Background To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet age-related macular degeneration (AMD ... tomography (OCT), despite having received ...

MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage ...

Opens in a new tab or window A retrospective review of home-based optical coherence tomography (OCT) monitoring for neovascular age-related macular degeneration (AMD) found that treatment should ...

AMD's data center business revenue surged 122% to $3.5 billion Analysts believe Nvidia will maintain majority market share in AI chips AMD expects Q4 revenue of $7.5 billion, below estimates Oct ...